About Us

About Us

Metabomed is a drug discovery company in the field of cancer metabolism. The company is developing a proprietary target identification platform based on computational biology, genomics and metabolomics. The platform identifies metabolic pathways that arise uniquely in cancers and are essential for their growth. These discoveries are used to develop small molecules that specifically target the reprogrammed cancer cells’ metabolism to halt their growth. Since these molecules inhibit divergent pathways that are specific to cancer cells, these therapies will not damage healthy surrounding tissues.
Metabomed is a privately held company based in Israel and supported by the groundbreaking science of its scientific founders.

  • Leadership

  • By focusing on metabolic addiction and synthetic lethality, our approach is uniquely tailored to the patients’ onco-genetic landscape – to generate personalized and precise therapies while reducing drug-induced toxicity. Metabomed was founded based on the groundbreaking work of our founders, who are charting new ways to identify a wealth of potential therapeutic targets.

Management

  •  
  • Dr. Simone Botti

    Dr. Simone Botti

    CEO
  •  
  • Dr. Andreas Goutopoulos

    Dr. Andreas Goutopoulos

    Chief Scientific Officer
  • Dr. Omri Erez

    Dr. Omri Erez

    Vice President, Biology
  • Dr. Philippe Nakache

    Dr. Philippe Nakache

    Vice President, Chemistry

  • Dr. Simone Botti

    Dr. Simone Botti
    CEO

  • Dr. Botti has been Metabomed’s CEO since July 2016. Simone co-founded Metabomed while he was Head of the Israel Bioincubator Fund at Merck Ventures, which he joined in 2011. During his tenure at Merck Ventures Dr. Botti set up the Israel Bioincubator Fund, and established a number of early stage companies. Previously, he was Vice President, Business Development at RAD Biomed Accelerator, one of Israel’s leading Life science incubators. Prior to that, he was Senior Director of Business Development at Cogenics. He also served as a Board Member of IATI, the Israel Advanced Technology Industries association. Dr. Botti holds a PhD in Chemistry from the Weizmann Institute of Science, where he received the “Dov Elad” prize in Structural Biology and was NIH–ADDP Fellow at Northwestern University Medical School in Chicago.


  • Dr. Andreas Goutopoulos

    Dr. Andreas Goutopoulos
    Chief Scientific Officer

  • Andreas joined Metabomed as CSO in November 2018, and brings close to 20 years of industrial drug discovery experience to the role. Prior to joining Metabomed, he was the Head of Chemistry at EMD Serono, for over a decade. He has been involved in the discovery of over a dozen molecules that have entered clinical trials in various therapeutic areas including Oncology, Neurodegeneration, Immunology and others. Some of the compounds that he and his group have invented include Evobrutinib, a Btk inhibitor, currently in several Phase II studies, Pimasertib, a MEK inhibitor for Oncology and others. Andreas is Adjunct Professor at the Center for Drug Discovery at Northeastern University. He holds a Ph.D. from University of Connecticut, where he worked in the area of Cannabinoid Receptors and related enzymes.

  • Dr. Omri Erez

    Dr. Omri Erez
    Vice President, Biology

  • Dr. Erez joined Metabomed as VP Biology in 2014, and brings with him more than a decade of experience in drug discovery. Prior to joining Metabomed, Dr. Erez worked at Proteologics, where he served as the Head of Biology from 2005 to 2008 and as the Head of Discovery from 2008 until November 2013. As the Head of Discovery, Dr. Erez led a group of researchers focusing on drug discovery in the ubiquitin field. Dr. Erez holds a BA in Biology from the Hebrew University of Jerusalem and a MSc and PhD in Biology from the Weizmann Institute of Science.

  • Dr. Philippe Nakache

    Dr. Philippe Nakache
    Vice President, Chemistry

  • Dr. Nakache joined Metabomed as Vice President of Chemistry in April 2014, and has over a decade of drug discovery and medicinal chemistry experience. Prior to that, Dr. Nakache served as Head of Chemistry of Proteologics from 2006 to 2013. He earned a MSc from Universite de Mediterranee in Marseille, France and a PhD in organic chemistry from Bar-Ilan University. He was an Postdoctoral Fellow at the Hanessian Laboratory at the Universite de Montreal.

Board of Directors

  •  
  • Prof. David Aviezer

    Prof. David Aviezer

    Chairman of the Board
  •  
  • Dr. Jasper Bos

    Dr. Jasper Bos

  • Dr. Ilka Wicke

    Dr. Ilka Wicke

  • Prof. Eyal Gottlieb

    Prof. Eyal Gottlieb

    Technion-Israel Institute of Technology
  • Mr. Ohad Hammer

    Mr. Ohad Hammer

  • Dr. Pini Orbach

    Dr. Pini Orbach

  • Dr. Denis Patrick

    Dr. Denis Patrick


  • Prof. David Aviezer

    Prof. David Aviezer
    Chairman of the Board

  • Prof. Aviezer has 20 years of experience in senior biotechnology executive management, advancing products from early-stage research up to their approval by FDA and into commercialization. From 2002 through 2014 he served as President and Chief Executive Officer of Protalix BioTherapeutics, a biotechnology company whose shares are publically traded on the New York Stoick Exchange (NYSE:PLX). Prof. Aviezer has hands on experience in creating strategic partnerships and research agreements as well as raising capital in the private and public markets. Before joining Protalix, Prof. Aviezer served as General Manager of ProChon Biotech/CTI, a private biotechnology company focused on orthopedic and growth disorders. Prior to that, he was a visiting scientist at the Medical Research Division of Cyanamid -Wyeth, in Pearl River, New York. Prof. Aviezer serves an adjunct associate Professor in the Biotechnology department of Bar-Ilan University, Israel. He has served as a member of many public committees and boards including the Israeli National Technology Committee and the Israeli Chief Scientist committee. He is the recipient of several awards including the Clore Foundation Award and the J.F. Kennedy Scientific Award. He holds a PhD in Molecular Biology and Biochemistry from the Weizmann Institute of Science and an MBA from the Bar-Ilan University Business School.


  • Dr. Jasper Bos

    Dr. Jasper Bos

  • Dr. Bos joined the previous biopharma fund MS Ventures in 2009 and transitioned to Vice President leading the Healthcare team for the current fund in 2016. Previously, he was instrumental in founding IFHA, Investment Fund for Health in Africa, a private equity fund backed by large Dutch and international institutional investors. He was responsible for the structuring and capital raise of IFHA and negotiated and managed private equity investments in emerging economies in the healthcare and insurance sectors. Before IFHA, Dr. Bos worked as health economics and strategy manager at the Netherlands Vaccine Institute. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands and has published more than 30 articles on health economics and vaccines.

  • Dr. Ilka Wicke

    Dr. Ilka Wicke

  • Dr. Ilka Wicke, serves as Investment Manager of Boehringer Ingelheim Venture Fund L.P. She joined Boehringer Ingelheim in 1996 as head of an interdisciplinary research laboratory specializing in new drug discovery approaches. After that, she spent more than 13 years in the Corporate Licensing Division of Boehringer Ingelheim where she was responsible for the evaluation, negotiation and management of several global licensing transactions. Subsequently Dr. Wicke joined the Corporate Licensing group as head of the business advisory teams for oncology, urology and metabolism where she was responsible for the identification and evaluation of pre-clinical and clinical licensing opportunities as well as structuring and negotiating technology and licensing agreements. Dr. Wicke later joined the transaction group of Corporate Licensing where she was responsible for the negotiation and conclusion of a variety of global licensing agreements. She serves as a Director of Boehringer Ingelheim and PROMETHERA Biosciences S.A./N.V., Metabomed and Pcovery ApS. Dr. Wicke spent a year as a postdoctoral fellow at the Sloan Kettering Cancer Center in New York investigating retroviral gene therapy approaches to stimulate anti-tumor responses. She has a PhD in Organic Chemistry from the Johann Wolfgang Goethe University in Frankfurt.

  • Prof. Eyal Gottlieb

    Prof. Eyal Gottlieb
    Technion-Israel Institute of Technology

  • Prof. Gottlieb is the Director of the Laura and Isaac Perlmutter Metabolomics Centre, at the Technion Integrated Cancer Center, Faculty of Medicine, Haifa, Israel. He received his BSc (1990) in Agricultural Sciences from the Hebrew University of Jerusalem, and an MSc (1993) and a PhD (1999) in Molecular Cell Biology from the Weizmann Institute of Science. In 1998 Prof. Gottlieb moved to the University of Chicago as an EMBO postdoctoral fellow to study the metabolic regulation of cell death and in 2000 he became a Leukemia and Lymphoma Society Special Fellow at the University of Pennsylvania, where he specialized in cancer metabolism. Since 2003, he serves as a Research Group Leader at the Cancer Research-UK, Beatson Institute in Glasgow, UK where he continues to work on cancer metabolism and established a metabolomics facility. In 2009 Prof. Gottlieb was appointed a Professor of Molecular Cell Biology at the University of Glasgow and from 2013 he is the Director of the Beatson’s Cancer Metabolism Research Unit. In 2016, Prof. Gottlieb moved to the Faculty of Medicine at the Technion-Israel Institute of Technology. Beyond his academic research activities, Prof. Gottlieb is a member of several Editorial Boards and he served as an adviser and collaborator in many pharmaceutical and biotech companies, including AstraZeneca and Astex Pharmaceuticals.

  • Mr. Ohad Hammer

    Mr. Ohad Hammer

  • Mr. Hammer is a Partner at Pontifax, a healthcare-dedicated VC fund, where he is in charge of scouting and evaluating new investment opportunities. He currently serves on the Boards of several of Pontifax’s portfolio companies, including Eyevensys, Keros, TargEDys and Zolex. He holds a MS in molecular biology from Tel Aviv University.

  • Dr. Pini Orbach

    Dr. Pini Orbach

  • Dr. Orbach is the Head of Pharma at Arkin Holdings and is a board member of several of its pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, where he shares his extensive hands-on drug development and business experience. Early in his career he worked in US-based companies, such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ, EPIX), as well as Israeli-based companies such as, cCAM BioTherapeutics – a cancer immunotherapy company, which was sold to Merck in 2015 for $605M. Dr. Orbach received his PhD, from the Department of Physiology and Functional Genomics at the University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, MGH – Harvard Medical School.

  • Dr. Denis Patrick

    Dr. Denis Patrick

  • Denis Patrick PhD is Vice President, WRD and Head of Oncology External Science & Innovation (ES&I), the R&D Lead for the Innovative Medicines Initiative at Pfizer, and Managing Partner of Pfizer Ventures. Denis capitalizes upon his experience in evaluating external opportunities that are focused on areas that complement Pfizer Oncology Research interests to identify and manage equity investments. He is currently responsible for managing investments in AnTolRx, Encycle, NextCure, and Metabomed. Denis previously worked for several large pharma oncology organizations, including Merck, DuPont Pharma, and GSK. Prior to coming to Pfizer, Denis contributed significantly to several oncology drug discovery efforts that led to the approval of three marketed therapeutic agents including nelarabine, trametinib, and dabrafenib.
    Denis received his BS in Biochemistry from SUNY, a MS in Biology from UCSD and a PhD in Biochemistry from the University of Pennsylvania.

Scientific Advisory Board

  • Prof. Eytan Ruppin, MD PhD - Founder

    Prof. Eytan Ruppin, MD PhD - Founder

    National Cancer Institute NIH
  • Prof. Eyal Gottlieb, PhD - Founder

    Prof. Eyal Gottlieb, PhD - Founder

    Technion-Israel Institute of Technology
  • Prof. Tomer Shlomi, PhD - Founder

    Prof. Tomer Shlomi, PhD - Founder

    Technion-Israel Institute of Technology
  • Dr. Harry Finch, PhD

    Dr. Harry Finch, PhD

  • Prof. Giulio Draetta, MD, PhD

    Prof. Giulio Draetta, MD, PhD

    MD Anderson Cancer Center
  • Dr. Kim Arndt, PhD

    Dr. Kim Arndt, PhD

    Pfizer
  • Prof. Eytan Ruppin, MD PhD - Founder

    Prof. Eytan Ruppin, MD PhD - Founder
    National Cancer Institute NIH

  • Prof. Ruppin is currently Chief of the Cancer Data Science Lab (CDSL)  at the US National Cancer Institute (NCI, NIH). He is an International leader in developing and studying models of cancer metabolism and genomics.

  • Prof. Eyal Gottlieb, PhD - Founder

    Prof. Eyal Gottlieb, PhD - Founder
    Technion-Israel Institute of Technology

  • Prof. Gottlieb is one of the Founders of Metabomed and is the Laura and Isaac Perlmutter Chair of Cancer Biology and the Director of the Metabolomics Centre, at the Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel. Previously, he was a Professor at the Cancer Research UK, Beatson Institute, Glasgow, UK.

  • Prof. Tomer Shlomi, PhD - Founder

    Prof. Tomer Shlomi, PhD - Founder
    Technion-Israel Institute of Technology

  • Prof. Shlomi is Head of the Computational Biology Lab in the Department of Computer Science and member of the Lokey Center for Life Science and Engineering at Technion. Prof. Shlomi is an international leader in integrated experimental-computational research of cancer metabolism.

  • Dr. Harry Finch, PhD

    Dr. Harry Finch, PhD

  • Dr. Finch has significant experience within the pharmaceutical industry, specializing in medicinal chemistry, drug discovery and development. After his PhD in Organic Chemistry, Dr. Finch worked at Ciba-Geigy AG, Roche and Allen & Hanburys Limited / GlaxoWellcome plc where he became director of Chemistry. Dr. Finch is co-inventor of GSK’s successful asthma drug salmeterol (Serevent). Since 2001 Dr Finch has held executive / non-executive director roles in Argenta Discovery, Pulmagen and Pulmocide, and is currently involved with C4X Discovery and Artios Pharma.

  • Prof. Giulio Draetta, MD, PhD

    Prof. Giulio Draetta, MD, PhD
    MD Anderson Cancer Center

  • Dr. Draetta, is currently Senior Vice-President, Therapeutics Discovery, Sewell Family Chair in Genomic Medicine, and the Moon Shots Program Co-Leader at The University of Texas MD Anderson Cancer Center. Previously, Dr. Draetta served as the Head of Oncology Drug Discovery at Pharmacia and Merck, and also held academic appointments at Cold Spring Harbor Laboratory, the European Molecular Biology Laboratory, the European Institute of Oncology, the Dana Farber Cancer Institute. His own research focuses on identifying and targeting critical metabolic and epigenetic vulnerabilities in pancreatic and brain cancers.

  • Dr. Kim Arndt, PhD

    Dr. Kim Arndt, PhD
    Pfizer

  • Kim Arndt, PhD, is currently Vice President of Oncology Research Strategy at Pfizer. In 1996, Dr. Arndt moved to Wyeth Research from Cold Spring Harbor Laboratory. Wyeth was subsequently acquired by Pfizer. While employed by Wyeth, Dr. Arndt’s group discovered bosutinib, which is currently approved for CML. Currently, Dr. Arndt is involved in Pfizer’s internal strategy for preclinical oncology research and also strategy for external opportunities.

Investors

  • Investors
  • Investors
  • Investors
  • Investors
  • Investors
  • Investors